Stada Arz and mAbxience to negotiate over adalimumab biosimilar
German drugmaker Stada Arzneimittel (SAZ: GR) and the biotech specialist mAbxience have agreed to negotiate over the in-licensing of an adalimumab (Humira) biosimilar.
The letter of intent stipulates that the two negotiating parties will come to a decision within the next six months. The original product, AbbVie’s (NYSE: ABBV) Humira,is the world's top-selling biopharmaceutical with a sales volume in 2013 of around $10.66 billion in 2013.
With these negotiations, Stada continues its longstanding strategy of targeted in-licensing of selected biosimilars; a strategy with which the group is continuously expanding its portfolio of quality products at comparably favorable conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze